Ewing Sarcoma (ES) is a highly aggressive bone tumor with peak incidence in the adolescent population. It has a high propensity to metastasize, which is associated with dismal survival rates of approximately 25%. To further understand mechanisms of metastasis we investigated microRNA regulatory networks in ES. Our studies focused on miR-130b due to our analysis that enhanced expression of this microRNA has clinical relevance in multiple sarcomas, including ES. Our studies provide insights into a novel positive feedback network involving the direct regulation of miR-130b and activation of downstream signaling events contributing toward sarcoma metastasis. Specifically, we demonstrated miR-130b induces proliferation, invasion, and migration in vitro and increased metastatic potential in vivo. Using microarray analysis of ES cells with differential miR-130b expression we identified alterations in downstream signaling cascades including activation of the CDC42 pathway. We identified ARHGAP1, which is a negative regulator of CDC42, as a novel, direct target of miR-130b. In turn, downstream activation of PAK1 activated the JNK and AP-1 cascades and downstream transcriptional targets including IL-8, MMP1 and CCND1. Furthermore, chromatin immunoprecipitation of endogenous AP-1 in ES cells demonstrated direct binding to an upstream consensus binding site within the miR-130b promoter. Finally, small molecule inhibition of PAK1 blocked miR-130b activation of JNK and downstream AP-1 target genes, including primary miR-130b transcripts, and miR-130b oncogenic properties, thus identifying PAK1 as a novel therapeutic target for ES. Taken together, our findings identify and characterize a novel, targetable miR-130b regulatory network that promotes ES metastasis.
Introduction
Ewing sarcoma (ES) is the second most common bone tumor in children and adolescents. Tumors often arise in the central axis and are identified by the presence of the oncogenic EWS-FLI1 fusion transcript. 1 Treatment consists of surgery and/or radiation therapy along with high dose cytotoxic systemic chemotherapy that has improved survival rates for patients with localized disease to approximately 70-75%. However, ES has a high propensity for metastasis to the lung, liver, and other bones, which are associated with extremely poor survival rates of approximately 25% that have remained stagnant over the past 30 years. 2 Therefore, understanding the biology of metastatic disease is of utmost clinical importance due to high mortality and morbidity ES patients.
MicroRNAs (miRNAs) are 18-22 nucleotide noncoding RNAs that have the ability to regulate protein translation and degradation through complementary binding to target mRNAs. 3 Recently, miRNAs have emerged as key regulators of numerous normal cellular processes such as proliferation, growth, differentiation, and apoptosis. Although miRNAs are critical for normal cellular homeostasis, a vast amount of miRNA research demonstrates that miRNAs are often aberrantly expressed in various neoplasms and can promote aggressive, metastatic disease.
Accumulating evidence suggests miR-130b is overexpressed in a number of malignancies and therefore acts as an oncomiR in these tumors. [7] [8] [9] It has been shown that overexpression of miR130b increases stemness and chemoresistance in glioblastoma and increases cell migration and invasion in glioma. 10, 11 Furthermore, miR-130b was identified as oncogenic miR and is part of pan-cancer oncogenic superfamily that targets key pathways often deregulated in cancer including p53 and TGFb. 12 The majority of miR-130b studies have been in epithelial based tumors; but several sarcomas, including leiomyosarcoma, osteosarcoma, and ES have shown enhanced expression of miR130b. [13] [14] [15] Overexpression of miR-130b correlated with poor event free survival and overall survival in ES; however, its function and role in dictating sarcoma biology and metastasis is not understood. 14 In addition, the transcriptional regulation and downstream gene regulatory networks of miR-130b have not been well elucidated in sarcomas.
There are relatively few studies dissecting the molecular alterations of metastasis in ES. Prior studies have highlighted that alterations in the cytoskeleton and Rho GTPases may be important for the promotion of metastasis in ES. 16, 17 The Rho GTPase encompass the Rho, Rac, and Cdc42 subfamilies which act as molecular switches activated in response to cellular stimuli such as, growth factors. 18 Upon activation, Rho GTPase signal through several effector proteins including, p21 activated kinases (PAKs) to mediate changes in cytoskeleton architecture, cell cycle, and gene transcription. 18 PAKs are serine/threonine kinases that function as downstream effectors for several oncogenic signaling networks and alterations in PAKs have been attributed to carcinogenesis and metastasis in several tumors. 19, 20 Upon activation PAKs can phosphorylate various downstream effectors including c-JUN N-terminal kinase (JNK), with the subsequent phosphorylation and nuclear localization of key oncogenic transcription factors such as Activator Protein 1 (AP-1), which is composed of the members of the JUN, FOS, MAF, and ATF protein families. 21, 22 Active AP-1 in the nucleus binds preferentially, to 12-o-tetradecanoylphorbol-13-acetate (TPA) responsive elements in canonical target gene promoters such as CCND1, MMP3, and IL-8. [23] [24] [25] [26] The role of PAK1 has been studied in many neoplasms, however; the function and contribution of PAK1 in ES tumorigenesis and metastasis is yet to be explored.
Our studies investigated the oncogenic role of miR-130b in ES, where we identified a novel miR-130b-AP-1 signaling axis that promotes transcription and activation of miR-130b and subsequent contributions to the invasive and metastatic properties of ES.
Materials and Methods

Cell culture and transfection
Human ES cell lines TC71, MHH-ES1, and A4573 were grown in RPMI 1640 Medium supplemented with 10% fetal bovine serum (FBS; HyClone, Thermo Fisher Scientific, Austria), 100 U/ml penicillin and 100 lg/ml streptomycin in a humidified atmosphere of 5% CO 2 at 378C. TC71 cells were derived from the humerus of male ES patient with progressive disease. MHH-ES-1 cells were derived from the ascites fluid of male ES patient with a primary tumor in the left pelvis. All cell lines were authenticated at the MD Anderson Characterized Cell Line Core (CCLC) Facility prior to studies being initiated. Cell lines were validated by STR DNA fingerprinting using the Promega 16 High Sensitivity STR Kit (Catalog # DC2100). The STR profiles were compared to online search databases (DSMZ/ATCC/JCRB/RIKEN) of 2,455 known profiles; along with the MD Anderson CCLC database of 2,556 know profiles. The STR profiles matched known DNA fingerprints or were unique. TC71 and MHH-ES1, A4573 cells were kindly provided by Dr. David Loeb (Johns Hopkins Children's Center, Baltimore, MD, 2008).
RNA oligoribonucleotides were transfected using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA). A final concentration of 30 nM RNA miRNA mimics, 100 nM miRNA inhibitors, or 10 nM siRNA pool was used for each transfection, unless otherwise indicated. Co-transfection of the RNA duplex and plasmid DNA were conducted using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). All transfections were performed in accordance with the manufacturer's protocol.
RNA oligoribonucleotides, plasmids, and inhibitors
All RNA oligoribonucleotides and negative controls were purchased from Ambion (Austin, TX). mirVana miRNA mimics and inhibitors corresponded to the mature miR-130b. OnTarget Plus siRNA pool to ARHGAP1 was purchased from Dharmacon (Lafayette, CO). FRAX597 and IPA3 were purchased from Tocris (Minneapolis, MN). JNK-IN-8 was purchased from Sigma-Aldrich (St. Louis, MO).
The miR-130b expression plasmid, pEZX-MR03, was purchased from GeneCopoeia (GeneCopoeia Inc., Rockville, MD). For generation of stable cell lines, cells were transfected with miR130b using Lipofectamine 2000. A total of 48 hr post transfection What's new? Ewing sarcoma (ES) is an aggressive malignancy of bone with a tendency to metastasize, resulting in poor prognosis. Little is known, however, about the molecular mechanisms involved in metastatic ES. Here, enhanced expression of the microRNA miR-130b was found to directly regulate ARHGAP1, a Rho-type GTPase activating protein, in ES cells. Enhanced miR-130b stimulated the CDC42/PAK1/AP-1 axis, a pathway activated by Rho GTPase signaling, resulting in the activation of downstream targets, including AP-1. AP-1 bound directly to the miR-130b promoter, fueling a positive feedback loop. The findings delineate a novel mechanism in sarcoma metastasis and reveal new therapeutic targets in ES.
media was replaced with selection media containing puromycin to generate TC71 control and TC71/130b cells. Cells were selected with puromycin and sorted for GFP expression. The miR-130b knockdown plasmid, pEZX-AMO3, was purchased from GeneCopoeia. MHH-ES-1 cells were transfected with anti-miR-130b plasmid to generate MHH control and MHH/anti-miR-130b cells. Cells were selected with hygromycin and sorted for mCherry expression. Cells were selected with 2 lg/ml Puromycin and 200 lg/ml Hygromycin, 72 hr post transfection. Bioinformatics analysis predicted one conservative miR-130b binding site in ARHGAP1 3 0 -UTR. The ARHGAP1 3 0 -UTR construct was a generous gift from the Kurie Lab (M.D. Anderson, Houston, TX) The mutant 3 0 -UTR, which contained the mutated sequence in the complementary site for the seed region of miR-130b, was generated using the Stratagene QuickChangeII Kit (Agilent Technologies, Santa Clara, CA).
Luciferase assay
For miR-130b targeted 3 0 -UTR assays, TC71 cells in a 6-well plate were co-transfected with 250 ng of the indicated hRL (Renilla luciferase)-ARHGAP1 wild-type or mutant reporter plasmids and 30 nM of either miR-130b or scrambled control mimics. After 48 hr, Firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter System (Promega, Madison, WI) according to the manufacturer's instructions. Renilla luciferase activity of each sample was normalized by Firefly luciferase activity.
CDC42 activity assay
CDC42 activation was measured with a CDC42 G-LISA Activation Assay (Colorimetric format) purchased from Cytoskeleton Inc. (Denver, CO). Briefly, TC71 cells were transfected with 30 nM miR-130b mimics or scrambled control. 48 hr post transfection cells were harvested and processed according to the manufacturer's protocol. Activity of CDC42 was measured as colorimetric change in absorbance at 490 nM.
Microarray profiling
Briefly, RNA samples were isolated from TC71 cells transiently expressing miR-130b mimic or a scrambled control for target preparation. High quality total RNA was amplified and purified using the Illumina TotalPrep RNA Amplification Kit (Ambion, Cat. no. IL1791) following the manufacturer's instructions. An aliquot of 750 ng of amplified products was loaded on Illumina HumanHT-12 v4 Expression BeadChip arrays and hybridized at 588C in an Illumina Hybridization Oven (Illumina, San Diego, CA; Cat. no. BD-103-0204) for 17 hr, washed and incubated with straptavidin-Cy3 to detect biotin-labeled cRNA on the arrays. Arrays were dried and scanned with the BeadArray Reader (Illumina). Data were analyzed using the Genome Studio software (Illumina).
The microarray data were generated by Table S3 .
Ewing sarcoma patient samples
The research, H-32129, was approved by the Institutional Review Boards for Baylor College of Medicine and Affiliated Institutions (IRB00002649). The BCM IRB has approved a waiver of consent/HIPAA authorization and has determined that all requirements are met by this protocol in order to grant the waiver. Patient clinical annotations are outlined in Supporting Information Table S2 .
Gene ontology analysis
Differentially expressed genes that were differences of 1.5-fold change and p-values, as evaluated by two tailed t-test, p < 0.05 were subjected to gene ontology analysis using Thomson Reuters Metacore TM program.
Reverse phase protein array
Reverse phase protein array assays were carried out as described previously with minor modifications. 29 Additional details are described in Supporting Information "methods."
Western blot analysis
Briefly, total cell lysates were isolated in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 lysis buffer supplemented with protease inhibitors (Complete mini, Roche, Indianapolis, IN) and phosphatase inhibitors (Sigma, P0044 and P5726). Nuclear lysates were isolated utilizing the NE-PER nuclear and cytoplasmic extraction reagents (ThermoScientific, Grand Island, NY, 78833) following the manufacturer's instructions. Lysates were boiled in NuPAGE LDS sample buffer (Invitrogen), separated on NuPAGE Novex 4-12% Bis-Tris Gels (Invitrogen), and transferred to polyvinylidene difluoride (PVDF) membranes. Blots were incubated sequentially overnight with primary and secondary antibodies. Immunoreactive signals were developed with ECL kit (Thermo Scientific, Waltham, MA). The antibodies used for immunoblotting were as follows: rabbit monoclonal antibodies (Ab) Phospho-PAK1 (Thr423)/PAK2 (Thr402) Antibody (2601) 
Chromatin immunoprecipitation
ChIP assay was performed using EZ-Magna ChIP TM A Chromatin Immunoprecipitation Kit (Cat# 17-408, Millipore) according to the manufacturer's instructions. Briefly, MHH-ES1 cells were then crosslinked using formaldehyde to a final concentration of 1%, and genomic DNA sonicated using an EpiShear TM Probe Sonicator to generate 500 bp fragments.
Cells were sonicated at 35% amplitude for 10 sec pulses and 30 sec rest for a total of 10 cycles. Soluble chromatin was then immunoprecipitated with a c-JUN antibody and amplified using specific PCR primers for the AP-1 binding site.
Cell proliferation assay
Growth assays were assessed by plating 1,000 cells per well in triplicate per day for 4 days in a 96-well plate unless otherwise indicated. Cell proliferation was detected through the addition of the colorimetric reagent Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan), according to the manufacturer's instructions (Cell counting kit-8 (CCK-8) assay kit; Dojindo Laboratories). Each value represents the triplicate average for that day.
Migration and invasion assay
Migration/Invasion assays were analyzed in a 24-well Boyden chamber with an 8-lm pore size polycarbonate membrane (Corning Glass Works, Corning, NY). For invasion assays, to mimic the extracellular matrix, chambers were coated with 30 mg/ml collagen and incubated at 378C overnight. Cells were suspended in 100 ll serum-free RPMI and added to the upper chamber, whereas the lower compartment was filled with 300 ll RPMI containing 10% FBS. After incubation at 378C for the 24 hr, cells were fixed and stained with 0.1% crystal violet. The cells on the top layer were removed with a cotton swab. All the migrated cells on the lower membrane were quantified using ImageJ. Invasion assay was done by the same procedure, except that the membrane was coated with collagen (3432-005-01, R&D Systems, MN) before adding cells to the upper chamber.
In vivo xenograft assay
A total of 1 3 10 6 TC71 cells stably overexpressing miR-130b or scrambled control were injected into the tail vein of 10 (5 per group) Rag2 2/2 mice. Six weeks post injection all animals were sacrificed and tissues were isolated. For the MHH-ES1 studies, a total of 10 (5 per group) NOD-SCID-gamma (NSG) mice were injected with 1 3 10 6 cells stably expressing antimiR-130b or a scrambled control. All mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Six weeks post injection all mice were sacrificed and tissues were isolated. All animal experiments were conducted according to institutional animal care and use committee protocols after approval was obtained from the BCM Institutional Review Board (BCM Animal Protocol AN-5225).
Immunohistochemistry
At the time of sacrifice, lung tissue was inflated with formalin, paraffin embedded, sectioned, and stained with hematoxylin and eosin. Slides were scanned in the Department of Veterinary Medicine and Surgery at the MD Anderson Cancer Center. Stained tumor sections were scanned, and the number of lung nodules per specimen was quantified utilizing the Aperio ImageScope Viewer (Leica Biosystems, Buffalo Grove, IL).
Clinical significance assessment of miRNA expression in sarcoma patients
We evaluated first the prognostic significance of miRNA expression in the TCGA Sarcoma patient cohort (https://tcga-data.nci. nih.gov/tcga/) using a methodology previously described. For each miRNA and for each sarcoma specimen, we computed the z scores for its expression within the TCGA cohort. Specimens were then ranked according to their individual miRNA z scores, and association with survival was evaluated by comparing the bottom half of the ranked specimens with the rest of the specimens (top half) using the log-rank test. Survival significance was evaluated by using the package survival in the R statistical system; significance was achieved for p values < 0.05. Next, we evaluated the association of miRNA expression with categorical clinical variables compiled for the TCGA Sarcoma patient cohort. We scored the specimens as described above, then collected the miRNA expression scores for each value of the categorical clinical variable. We evaluated association using the ANOVA method, as implemented in the R statistical system; significance was achieved for p values < 0.05.
Statistical analysis
The significant differences of control and miR-130b mimic or control versus anti-miR-130b under different conditions were determined by Student's t-test. p values <0.05 was considered significant. A two-sided Student's t-test (paired) was used to calculate the level of statistical significance for metastatic lesions in control/ miR-130b and control/anti-miR-130b mice. All tests of data were performed using GraphPad Prism.
Results
miR-130b is overexpressed in ES and promotes invasion, migration, proliferation in vitro
Ewing sarcoma is a rare but aggressive pediatric tumor, therefore access to adequate numbers of patient samples is limited.
However, using institutional patient tumor samples, we analyzed the relative abundance of miR-130b and determined relative expression levels in ES compared to normal human mesenchymal stem cells (hMSCs). We noted enhanced expression of miR-130b in the tumor specimens compared to MSCs (Fig. 1a) . Furthermore, analysis of The Cancer Genome Atlas (TCGA) sarcoma cohort suggests there is clinical significance of high miR-130b in not only pediatric, but also adult sarcomas. Specifically, we analyzed the expression and clinical outcomes of miR-130b in (TCGA) sarcoma cohort and noted high miR130b expression correlates with poor survival (Supporting Information Fig. S1 ), therefore suggesting the importance of this microRNA, and its downstream regulation across the various sarcoma subtypes. We then examined the expression of miR-130b in ES cell lines relative to MSCs and decided to overexpress miR-130b in TC71 cells and inhibit miR-130b in MHH-ES1 cells for functional studies (Fig. 1b) . To determine the functional significance of miR-130b in ES, we performed complementary gain and loss of function studies. After determining relative expression of miR-130b in various ES cell lines (Fig. 1b) , TC71 and A4573 cells were transiently transfected with miR-130b mimics or a negative control and subjected to transwell assay. Overexpression of miR-130b increased the migratory and invasive capacity of TC71 and A4573 cells (Fig. 1c, Supporting Information Figs. S2a and S2b). Furthermore, overexpression of miR130b increased the proliferation of TC71 cells (Fig. 1e) . Conversely, loss-of-function studies demonstrated that inhibition of miR-130b levels in the MHH-ES1 cell line decreases tumor cell proliferation and invasive potential (Figs. 1d and 1f) . Taken together these results suggest miR-130b can contribute to the more aggressive, disseminated properties of ES.
miR-130b expression alters in vivo metastatic potential for ES
After determining miR-130b contributes to ES in vitro metastatic properties, we investigated the in vivo significance of miR-130b on ES metastatic potential. We performed both gain and loss-offunction studies using TC71 and MHH-ES1 ES cells, respectively, through tail vein injection of immunodeficient mice as described in methods section. Specifically, we injected stable TC71 control and TC71/130b overexpressing cells via tail vein into mice and six weeks post-injection all mice were sacrificed and necropsies performed. TC71/130b injected mice showed significantly increased number of metastatic lung nodules compared to the control mice at the time of sacrifice (Figs. 2a and  2b ). Subsequently, we injected stable MHH-ES1 control and MHH-ES1/anti-miR-130b ES cells via tail vein and observed significantly decreased metastatic liver lesions in the miR-130b knockdown mice compared to the control mice (Fig. 2c) . Thus, we demonstrate that in vivo miR-130b is able to significantly alter ES dissemination, with organ tropism most likely dependent on inherent properties of the cell line. TC71 has been shown to have the ability to metastasize to the lungs in prior studies, while our experience with MHH-ES-1 cells have demonstrated propensity for metastasis to the liver, which might be attributed to their derivation from ascites fluid of the abdomen. 30, 31 Overall our in vitro and in vivo studies provide convincing evidence that miR-130b contributes to metastatic properties and phenotype seen in ES tumors.
miR-130b promotes the activation of CDC42 through negative regulation of previously unknown target, ARHGAP1, in ES After determining the contributions of miR-130b toward the metastatic potential for ES, we were interested in determining miR-130b functional activities that could contribute toward driving ES metastasis. miRNAs are estimated to regulate approximately 30% of the genome through inverse relationships with target mRNAs. 32 To understand how miR-130b could regulate the transcriptome of ES, we performed gene expression profiling and subsequent validation of differentially expressed genes (Supporting Information Fig. S3a ). Pathway analysis using MetaCore TM software (Thomson Reuters) was performed on significant (p < 0.05) differentially expressed genes. We analyzed genes downregulated with transient miR-130b overexpression in TC71 cells and then overlapped these candidate genes with predicted targets of miR-130b by TargetScan. 32 The overlap resulted in approximately 70 genes (Supporting Information Fig. S3b ). Supporting Information Table S1 highlights the significant pathways altered, which included genes not only involved in cell morphology, but also interestingly significant alterations of genes involved in regulating migratory pathways, including the CDC42 pathway (Supporting Information Table S1 ). Subsequently, to investigate the functional significance of CDC42, we performed an ELISA assay to measure the activity of CDC42 in the TC71 miR-130b overexpressing cells. CDC42 is a member the RHO, RAC, and CDC42 subfamilies that make up the Rho GTPases. 33 In response to various cellular stimuli such as integrin engagement, growth factors, and stress, Rho GTPases are guanine exchange factors (GEFs) that act on numerous cellular processes such as proliferation, cytoskeletal remodeling, and gene transcription. Adding an extra layer of regulation, GTPase-activating proteins (GAP) hydrolyze GTP inactivating the GTPase. 34 We observed miR-130b activated CDC42, as measured by colorimetric ELISA, whereas total CDC42 protein levels remained unchanged (Fig. 3a) . Using the pathway analysis and TargetScan miRNA prediction algorithm to identify mRNAs that had seed sequence for miR-130b and functioned in CDC42 pathway, we identified ARHGAP1 as a putative target of miR-130b (Fig. 3b) , which was downregulated in our gene microarray. ARHGAP1 is a highaffinity negative regulator of CDC42 that hydrolyzes active CDC42 into the inactive GDP state. 35, 36 Previous studies investigating ARHGAP1 demonstrate that loss of ARHGAP1 leads to constitutive activation of CDC42 and subsequent downstream effector signaling. 37 We therefore hypothesized that downregulation of ARHGAP1 by miR-130b contributed to the observed activation of CDC42 in our cells. TC71 cells overexpressing miR-130b demonstrated downregulation of ARHGAP1 mRNA and protein by qPCR and western blot (Fig. 3c) . Conversely, knockdown of miR-130b in MHH cells resulted in modest mRNA, but significant protein level increases for ARHGAP1 (Fig. 3d) . To determine whether or not this interaction was by direct binding, we used a luciferase reporter assay containing the ARHGAP1 3 0 -UTR to verify the interaction. miR-130b was able to significantly repress luciferase activity while the seed mutant restored luciferase expression (Fig. 3e) . Finally, using the publically available R2 Microarray visualization platform "http:// hgserver1.amc.nl/cgi-bin/r2/main.cgi" we noted that ARHGAP1 expression levels are adversely associated with event-free and overall survival rates for patients with ES (Fig. 3f) . These results suggest that interaction between miR-130b and ARHGAP1 is specific and demonstrate ARHGAP1 is a novel direct target of miR-130b that has clinical ramifications in patients with ES.
miR-130b promotes the activation of an oncogenic CDC42/PAK1/JNK gene regulatory network Upon activation, CDC42 signals downstream to PAK1, which autophosphorylates in response to CDC42 binding. 38, 39 In response to miR-130b overexpression, PAK1 has enhanced phosphorylation by immunoblotting analyses (Fig. 4a) . Conversely, knockdown of miR-130b resulted in decreased phospho-PAK1 levels (Fig. 4b) . Furthermore, we demonstrated that direct transient knockdown of ARHGAP1 expression mimicked the overexpression of miR-130b with enhanced downstream activation of PAK1 and c-Jun (Supporting Information Fig. S4a) .
PAK1 overexpression has been demonstrated in many tumors contributing to oncogenic signaling cascades, however the role and regulation of PAK1 in ES remains unknown. We observed an increase in the mRNA expression of PAK1 in ES patient samples and a negative correlation with ES patient survival (Supporting Information Figs. S4b and S4c). PAK1 links CDC42 to nuclear signals and cytoskeletal rearrangements. Expression levels of several cytoskeletal reorganization genes, n-WASP, SPEC1, and SPEC2 remained relatively unchanged when miR-130b is overexpressed suggesting miR-130b may be stimulating downstream PAK1 effectors (Fig. 4c) . Evidence suggests that PAK1 can signal through JNKs resulting in the activation of c-JUN. 21 Further investigation of our gene expression array revealed a dramatic upregulation of c-JUN and c-FOS (Fig.  4c) . Coinciding with the enhanced gene expression seen in the microarray, we performed reverse phase protein array (RPPA) analysis that showed upregulation of phosphorylated JNK, phosphorylated c-JUN, and c-JUN protein levels, which were subsequently validated by western blot analysis (Fig. 4d , Supporting Information Figs. S5a and S5b). Taken together, these data suggest that miR-130b regulation of CDC42 and PAK1 results in downstream activation of the JNK pathway.
In order to determine if the effects of miR-130b could be pharmacologically mitigated, we used an inhibitor of PAK1, IPA3. IPA3 acts as an allosteric inhibitor of PAK1 resulting in an unfavorable conformation of the PAK1 active site. 40 Using IPA3, the increased proliferation due to miR-130b in TC71 cells was attenuated (Fig. 4e) . Furthermore, IPA3 also reduced the c-JUN and JNK levels induced by miR-130b (Fig. 4f) . To provide confirmation that PAK1 inhibition can attenuate the effects of miR-130b, we used the PAK1 inhibitor FRAX597. 41 Treatment with FRAX597 rescued the proliferative effects or miR-130b (Supporting Information Fig. S4d) . Collectively, these data confirm a targetable CDC42/PAK1/JNK regulatory network promoted by miR-130b.
Downstream activation of AP-1 and target genes by miR-130b
The microarray data and RPPA provide evidence that miR130b induces the activation of JNK/SAPK and subsequent phosphorylation of its downstream target, c-JUN. The AP-1 transcription factor translocates to the nucleus upon activation and binds to the promoter region of target genes. To further confirm AP-1 is activated, we fractionated protein lysates from cells overexpressing miR-130b. Western blot analysis demonstrates that phosphorylated c-JUN and total c-JUN are increased in response to miR-130b overexpression but phospho-c-JUN is enriched in the nuclear fraction further confirming AP-1 is being activated (Fig. 5a ), while treatment with IPA3 and FRAX597 rescued the increased expression of c-JUN and AP-1 target genes (Fig. 5b, Supporting Information Figs. S4e and S4f). In addition, use of the AP-1 inhibitor, SR11302, and JNK1 inhibitor, JNK-IN-8 also suppressed miR-130b induced c-JUN and AP-1 target gene expression by qPCR, which further confirms miR-130b activation of this pathway (Supporting Information Fig. S4g) . Finally, knockdown of miR130b also decreased the expression of c-JUN and AP-1 targets by qPCR and western blot analysis, suggesting miR-130b is specifically mediating this oncogenic transcriptional program (Figs. 5c and 5d ). Taken together our results highlight that miR-130b and CDC42, PAK1, and AP-1 form a critical oncogenic network within ES.
AP-1 binds to the miR-130b promoter and regulates miR-130b transcription
The causes of miRNA dysregulation have been linked to numerous processes including chromosomal aberrations, miRNA processing defects, and transcription factor binding. 42 After demonstrating the functional significance of miR-130b in ES, we decided to look at the regulation of miR-130b. We analyzed an approximately 4 kb region upstream of the miR130b precursor using the UCSC ENCODE DNA browser (http://genome.ucsc.edu/). 43, 44 Utilizing the publically available ChIP-SEQ data in this region we observed an enriched H3K27ac region, which is associated with active enhancers. We next examined predicted transcription factor binding sites within this region. Interestingly, an AP-1 binding site was predicted approximately 1 kb upstream from the miR130b precursor (Supporting Information Fig. S6 ). In order to examine whether AP-1 was binding to the miR-130b promoter, we performed Chromatin Immunoprecipitation (ChIP) assays on endogenous levels of AP-1. Genomic DNA was isolated from MHH cells and a site-specific band was amplified using primers covering the AP-1 region from DNA immunoprecipitated with a c-JUN antibody indicating the occupancy of the transcription factor at the promoter of miR-130b (Fig. 6a) .
To understand if AP-1 is promoting transcription of miR130b we treated TC71 cells with 12-o-tetradecanoylphorbol-13-acetate (TPA), which is an activator of c-JUN and AP-1. TPA stimulation led to an induction of the pri-miR-130b transcript after just 4 hr suggesting AP-1 can quickly induce miR-130b expression (Fig. 6b) . The induction of the pri-miR130b transcript by TPA and the induction of JNK, c-JUN, and AP-1 target genes by overexpression of miR-130b suggest that a positive feedback loop is functioning to drive an oncogenic, metastatic gene regulatory network in ES. To further investigate the presence of a positive feedback loop, we overexpressed miR-130b in TC71 cells and treated the cells with IPA3. After treatment with IPA3, we observed a decrease in the pri-miR-130b transcript (Fig. 6c) . Furthermore, treatment of MHH cells with IPA3 also decreased the levels of the pri-miR-130b transcript (Fig. 6d) . In sum, these results suggest a positive feedback loop exists between miR130b expression and AP-1 activation. Specifically, miR-130b overexpression leads to the stimulation of CDC42 through downregulation of CDC42 negative regulator, ARHGAP1, which in turn leads to the autophosphorylation of PAK1 and the activation of AP-1 and its target genes. Subsequently, AP-1 promotes the expression of miR-130b, thus completing an oncogenic positive feedback loop in ES (Fig. 6e) .
Discussion miR-130b has been reported to have oncogenic properties in numerous cancers, but its direct targets and their function, along with the regulation of miR-130b, remain largely unknown. Here we demonstrate a previously unknown gene regulatory network regulated by miR-130b in ES that contributes metastatic phenotypes both in vitro and in vivo. We have further elucidated a mechanism in which miR-130b promotes sustained CDC42 activation through downregulation of ARHGAP1, a negative regulator of CDC42 and novel direct target of miR-130b. Prolonged activation of CDC42 by miR-130b leads to downstream AP-1 activation and target gene expression that promotes sarcoma invasion, migration, and proliferation. A positive feedback network was demonstrated by the ability of AP-1 to bind to the miR-130b promoter and induce transcription of the primary miR-130b. Finally, we could abrogate the effects induced by miR-130b and AP-1 using a PAK1 inhibitor, IPA3. p21 activated kinases are a group of serine threonine kinases that are key signaling nodes for the activation of pro-tumorigenic pathways including the activation of pathways involved in proliferation, evasion of apoptosis, and invasion. 45 Numerous studies have also demonstrated that PAKs are mutated, overexpressed, or activated in cancer, making them exciting therapeutic targets for anti-cancer therapies. 46, 47 Interestingly, the contribution of PAK1 in ES development and metastasis has been severely understudied, and inhibition of this signaling node, in combination with approved standard treatment protocols, may offer new therapeutic options for patients with metastatic disease. We have shown novel insights into the effects of PAK1 in ES. We demonstrate that PAK1 is upregulated in ES patient tumors, enhanced expression correlates with poor patient outcome, and the use of the PAK1 inhibitors IPA3 and Frax597 attenuate the pro-proliferative effects of miR130b. We did observe an increase in phospho-c-JUN levels with IPA3 which is most likely due to stress caused by treatment with IPA3. Furthermore, because c-JUN is downstream of stress response pathways, we did not observe a complete rescue in phosphorylation of c-JUN. However, these proof of principle studies demonstrate IPA3 and next generation PAK inhibitors such as, FRAX597 may prove promising to further test in an in vivo model for ES.
It is well known that miRNAs can have numerous targets, and therefore simultaneous effects within the cell. As mentioned above, we prioritized ARHGAP1-mediated signaling based on analysis of our microarray data demonstrating ARHGAP1 downregulation and components of the CDC42-PAK pathway were significantly altered. In addition, gene ontology analysis further suggested deregulation of other pathways, such as the ROBO pathway, but we were unable to validate these findings. PAK1 activation intersects the regulation of several oncogenic pathways and is known to have various downstream effectors involved in cytoskeleton remodeling. Overall our studies, including the analysis and integration of microarray and RPPA data, suggest that miR130b-mediated PAK1 activation of JNK signaling in contrast to traditional cytoskeleton remodeling genes. However, we cannot exclude other significant miR-130b mediated biological phenotypes in ES that might be worth exploring.
While we provide evidence of a novel regulatory mechanism in ES, these pathways can have various modes of activation. Several studies have demonstrated that EWS-FLI1 is capable of modulating miRNA expression; however, miR130b expression was not shown to be altered in these studies. 48, 49 While miR-130b has been independently shown to contribute to metastatic properties in other malignancies, we cannot exclude the contribution of the fusion transcript to aid in metastatic potential dictated by miR-130b. 7, 50 Overall, we highlight this as a potential mechanism to promote metastasis in ES, but cannot exclude other mechanisms of action such as input from other GTPases or components of the MAPK pathway. Future and ongoing studies include testing of relevant inhibitors of the MAPK and JNK as well as PAK1 in vitro and in vivo. In summary, our functional genomic studies demonstrate that miR-130b has significant impact on the phenotypes that contribute to metastatic foci formation. Our detailed molecular mechanism highlights the importance of miR-130b in sustaining an oncogenic signaling loop in ES while also elucidating novel druggable targets for the treatment of metastatic ES.
